Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intensive insulin therapy in critically ill patients.
van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. van den Berghe G, et al. Among authors: verwaest c. N Engl J Med. 2001 Nov 8;345(19):1359-67. doi: 10.1056/NEJMoa011300. N Engl J Med. 2001. PMID: 11794168 Free article. Clinical Trial.
Dehydroepiandrosterone sulphate in critical illness: effect of dopamine.
Van den Berghe G, de Zegher F, Wouters P, Schetz M, Verwaest C, Ferdinande P, Lauwers P. Van den Berghe G, et al. Among authors: verwaest c. Clin Endocrinol (Oxf). 1995 Oct;43(4):457-63. doi: 10.1111/j.1365-2265.1995.tb02618.x. Clin Endocrinol (Oxf). 1995. PMID: 7586621 Clinical Trial.
Pharmacokinetics of continuous renal replacement therapy.
Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Schetz M, et al. Among authors: verwaest c. Intensive Care Med. 1995 Jul;21(7):612-20. doi: 10.1007/BF01700172. Intensive Care Med. 1995. PMID: 7593908 Review. No abstract available.
Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Vlasselaers D, Schetz M, Verwaest C, Lauwers P, Bouillon R. Van den Berghe G, et al. Among authors: verwaest c. Clin Endocrinol (Oxf). 1996 Sep;45(3):341-51. doi: 10.1046/j.1365-2265.1996.00805.x. Clin Endocrinol (Oxf). 1996. PMID: 8949573 Clinical Trial.
The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R, Bowers CY. Van den Berghe G, et al. Among authors: verwaest c. J Clin Endocrinol Metab. 1997 Feb;82(2):590-9. doi: 10.1210/jcem.82.2.3736. J Clin Endocrinol Metab. 1997. PMID: 9024260 Clinical Trial.
Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, Verwaest C, Van der Vorst E, Lauwers P, Bouillon R, Bowers CY. Van den Berghe G, et al. Among authors: verwaest c. J Clin Endocrinol Metab. 1998 Feb;83(2):309-19. doi: 10.1210/jcem.83.2.4575. J Clin Endocrinol Metab. 1998. PMID: 9467533 Clinical Trial.
21 results